41,782 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Nykredit A S

Nykredit A S purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 41,782 shares of the biopharmaceutical company’s stock, valued at approximately $26,053,000.

Several other institutional investors also recently bought and sold shares of the business. B. Metzler seel. Sohn & Co. AG raised its stake in shares of Regeneron Pharmaceuticals by 37.5% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 4,472 shares of the biopharmaceutical company’s stock worth $2,788,000 after buying an additional 1,220 shares during the period. XML Financial LLC grew its stake in Regeneron Pharmaceuticals by 3.8% in the 2nd quarter. XML Financial LLC now owns 1,214 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 44 shares during the period. Independence Bank of Kentucky grew its stake in Regeneron Pharmaceuticals by 7.1% in the 2nd quarter. Independence Bank of Kentucky now owns 332 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 22 shares during the period. Triumph Capital Management increased its holdings in Regeneron Pharmaceuticals by 9.2% in the 2nd quarter. Triumph Capital Management now owns 414 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 35 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $567,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 4,146 shares of company stock valued at $3,432,488. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.0%

NASDAQ REGN opened at $843.47 on Friday. The business has a fifty day moving average price of $734.39 and a 200 day moving average price of $719.34. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $86.84 billion, a P/E ratio of 20.85, a P/E/G ratio of 1.67 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm posted $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. HSBC reduced their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Finally, Truist Financial raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $800.36.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
• Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.